Inoviv
Inoviv develop tailored biomarker tests to identify the right patients for trials and demonstrate treatment efficacy for novel therapies. Their tests support pharmaceutical companies in running successful clinical trials.
92% of clinical trials fail to gain drug approval, resulting in losses of ~$25 billion annually. Clinical trials that employ biomarker strategies for patient selection are 3x more likely to succeed. Biomarkers lie at the heart of the precision medicine revolution. They are an essential component of modern drug discovery and development, from demonstrating mechanisms of action to identifying and stratifying patients, monitoring therapeutic response and efficacy, and informing decision-making during clinical trials.
Inoviv’s solution is designed to enroll the right patients and demonstrate efficacy of new drugs, increasing clinical trial success rates by over 3x. Inoviv’s biomarker tests optimize patient enrolment into trials by identifying the ones who are most likely to respond to the specific drug, dramatically improving chances of statistically significant outcomes. Inoviv use a proprietary technology developed in-house that allows to measure 50+ fully calibrated molecules per biofluid sample, and develop bespoke tests specific to disease subtypes, which are ideal to support targeted therapies.
Founders
Michael Dove
CEO
Michael graduated from the University of Leeds. He began his career in consulting with Accenture in their Life Sciences division. He is specialized in life sciences technology deployment and worked with some of the largest pharmaceutical companies in the world on R&D.
Ernestas Sirka
CSO
Ernestas holds a First Class Honors Master’s in Molecular and Cellular Biology from the University of Bath. He spent time working for Pfizer on formulation research, before becoming a researcher in translational biomarkers at University College London.